T. Rowe Price Associates
OCRX

T. Rowe Price Associates’s Ocera Therapeutics, Inc. OCRX Stock Holding History

T. Rowe Price Associates’s Portfolio OCRX Stock Details OCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-31,942
Closed -$203K – 2587
2014
Q4 		$203K Sell
31,942
-500
-2% -$2.92K ﹤0.01% 2353
2014
Q3 		$159K Hold
32,442
– – ﹤0.01% 2397
2014
Q2 		$248K Sell
32,442
-45,419
-58% -$362K ﹤0.01% 2267
2014
Q1 		$821K Buy
+77,861
New +$1.11M ﹤0.01% 1742

Other funds holding OCRX

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
WMSA
Weiss Multi-Strategy Advisers New York $4.16B AUM 30.77% 1-Year Est. Return
OPPM
Opus Point Partners Management New York $55.3M AUM 7.48% 1-Year Est. Return

T. Rowe Price Associates's OCRX Position: Q1 2015 in Review

T. Rowe Price Associates sold out of Ocera Therapeutics, Inc. (OCRX) in Q1 2015, closing a stake of 31,942 shares — an estimated $203K sold.

T. Rowe Price Associates first reported a position in OCRX in Q1 2014 and held it in 4 quarters. The position peaked at $821K in Q1 2014. 34 funds tracked by Wall St. Rank hold OCRX as of Q1 2015.

  • T. Rowe Price Associates reported no remaining Ocera Therapeutics, Inc. position as of Q1 2015 after selling out during the quarter.
  • T. Rowe Price Associates sold 31,942 Ocera Therapeutics, Inc. shares in Q1 2015, an estimated $203K.
  • T. Rowe Price Associates first reported a position in Ocera Therapeutics, Inc. in Q1 2014 and held it in 4 quarters.
  • T. Rowe Price Associates's Ocera Therapeutics, Inc. position peaked at $821K in Q1 2014.
  • 34 funds tracked by Wall St. Rank held Ocera Therapeutics, Inc. as of Q1 2015.

Based on T. Rowe Price Associates's 13F filing for Q1 2015, filed 15 May 2015.